Strs Ohio Cerevel Therapeutics Holdings, Inc. Transaction History

Strs Ohio

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$38.96 - $42.75 $713,591 - $783,009	18,316 Added 140.89%	31,316 $1.28 Million
Q1 2024 May 13, 2024	BUY	$40.88 - $43.27 $130,816 - $138,464	3,200 Added 32.65%	13,000 $549,000
Q4 2023 Jan 30, 2024	SELL	$20.27 - $42.44 $8,108 - $16,976	-400 Reduced 3.92%	9,800 $415,000
Q2 2023 Jul 31, 2023	BUY	$23.9 - $35.38 $150,570 - $222,894	6,300 Added 161.54%	10,200 $324,000
Q1 2023 Aug 02, 2023	SELL	$22.82 - $35.32 $143,766 - $222,516	-6,300 Reduced 61.76%	3,900 $95,000
Q3 2022 Oct 27, 2022	BUY	$25.5 - $41.42 $58,650 - $95,266	2,300 Added 143.75%	3,900 $110,000
Q3 2021 Oct 22, 2021	SELL	$21.26 - $38.85 $140,316 - $256,410	-6,600 Reduced 80.49%	1,600 $47,000
Q2 2021 Jul 26, 2021	BUY	$12.56 - $29.69 $102,992 - $243,458	8,200 New	8,200 $210,000

5.04M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.